Developing highER-throughput zebrafish screens for in-vivo CNS drug discovery

The high prevalence of brain disorders and the lack of their efficient treatments necessitate improved in-vivo pre-clinical models and tests. The zebrafish (Danio rerio), a vertebrate species with high genetic and physiological homology to humans, is an excellent organism for innovative central nervous system (CNS) drug discovery and small molecule screening. Here, we outline new strategies for developing higher-throughput zebrafish screens to test neuroactive drugs and predict their pharmacological mechanisms. With the growing application of automated 3D phenotyping, machine learning algorithms, movement pattern- and behavior recognition, and multi-animal video-tracking, zebrafish screens are expected to markedly improve CNS drug discovery.

box for which is becoming increasingly diverse and efficient in zebrafish (Bernier et al., 2014;Kalueff et al., 2014b;Stewart et al., 2014a). Finally, larval and adult zebrafish screens are also useful for dissecting the drugs' psychopharmacological profiles (e.g., using multiple receptor agonists and antagonists prior to a more targeted rodent testing)-an approach that focuses on "core," evolutionarily conserved (and, thus, translationally more relevant) molecular pathways shared by zebrafish and humans (Kalueff et al., 2014a,b;Stewart et al., 2014a).
Current in-vivo zebrafish HTS typically utilize extensive or intensive approaches to generate "big data" for translational neuroscience research (Figure 1). For instance, applying a barcoding strategy (Glossary), extensive analyses of several basic locomotor and sleep/wake parameters in larval zebrafish have successfully identified neuroactive drugs from a large library of screened compounds Peterson, 2008, 2011;Kokel et al., 2010;Rihel et al., 2010;Laggner et al., 2012;Jin et al., 2013). Recent intensive studies analyzing 20-30 three-dimensional (3D) behavioral endpoints in adult zebrafish (Glossary , Supplementary Table 1S online), have detected potential commonalities and differences in profiles of several tested neuroactive drugs (Egan et al., 2009;Grossman et al., 2010;Wong et al., 2010;Cachat et al., 2011Cachat et al., , 2013. Tracking individual fish with one camera in 2D, or with two cameras in 3D, can generate up to 50-60 individual endpoints (see Supplementary Table 1S online for examples) which can be sensitive to neuroactive properties of the drugs. Tracing selected endpoints in zebrafish shoals, such as assessing the average inter-fish distance and velocity, is also possible in zebrafish models  (although more sophisticated computer tools and optimized animal tagging methods are needed to monitor each individual fish within the group). (B) Illustrates the potential of 3D behavioral video-tracking in zebrafish to predict drug pharmacology (also see Soleymani et al., 2014). In this example, top swimming combined with elevated angular velocity in zebrafish treated with a hallucinogenic drug phencyclidine (PCP, inset) shows a striking difference from control fish, supporting the value of various computer-based neural phenotypes for predicting the pharmacological profile of different CNS-active compounds. (C) Shows examples of representative 3D phenotypes for control fish and animals acutely exposed to several CNS drugs. LSD, Lysergic acid diethylamide (images: courtesy of Noldus IT, Netherlands, in collaboration with the Kalueff Laboratory, Stewart et al., 2014a). Note distinct patterns of locomotion evoked by drugs from different pharmacological classes (also see Cachat et al., 2011Cachat et al., , 2013Soleymani et al., 2014 for discussion).

Frontiers in Behavioral Neuroscience
www.frontiersin.org February 2015 | Volume 9 | Article 14 | 2 Figures 1, 2 further illustrate how a comprehensive evaluation of individual compounds can foster objective, computer-based prediction of the drugs' pharmacology. For example, phencyclidine (PCP) is a hallucinogenic glutamatergic antagonist that acutely evokes characteristic "top circling" behavior in zebrafish (Figures 1, 2). Assessed by elevated angular velocity and rotation index, this response is similar for anti-glutamatergic hallucinogens, but not other classes of hallucinogenic agents Neelkantan et al., 2013;. Analyzing such 3D profiles, it is therefore possible to generate decision trees for predicting the pharmacological profile of different groups of neuroactive compounds, based on zebrafish swimming patterns and their geometry (Figure 2) (Cachat et al., 2010(Cachat et al., , 2011Soleymani et al., 2014). Likewise, acute nicotine evokes characteristic top swimming along perimeter of the tank, strikingly differing from top circling (typical for many anti-glutamatergic drugs) or top surfacing without peripheral swimming (typical for serotonergic agents; Figure 1C) Neelkantan et al., 2013;. Importantly, such accumulation of large libraries of drugs' behavioral signatures in zebrafish can parallel the application of machine learning algorithms, leading to further refinement and optimization of the prediction of drugs' pharmacological profiles (Soleymani et al., 2014) (Figure 2C).

DEVELOPING HIGHER-THROUGHPUT ZEBRAFISH SCREENS
The choice between extensive and intensive analyses in zebrafish models no longer poses a critical dilemma for researchers, because modern information technology tools and the low cost of zebrafish (vs. rodent) assays markedly facilitate the collection and computer processing of data (Figures 2D,E). Here, we argue that the two strategies can now be co-applied in zebrafish screening studies, resulting in "higher-throughput" screens capable of generating "super-big data" (Figures 2D,E, Glossary). Enhancing the efficiency of zebrafish-based models for innovative CNS drug discovery, this strategy combines the advantages of the extensive approach (utilizing large numbers of drugs and animals tested) with the benefits of using extensive studies (focusing on a large number of phenotypes that help generate mechanistic insights; Figures 2D,E).
In addition to zebrafish's utility for HTS per se, this species also enjoys the advantage of having a sophisticated molecular genetic toolset developed for it. For example, traditional Nethyl-N-nitrosourea (ENU)-induced (Mullins et al., 1994) or viral vector-mediated (Amsterdam et al., 1999) mutagenesis and gene silencing using morpholinos complement other genetic tools recently developed for zebrafish, such as "gene-breaking transposon" (GBT) (Petzold et al., 2009) screens, "clustered regularly interspaced short palindromic repeats" (CRISPR) (Hwang et al., 2013), zinc finger nucleases (Doyon et al., 2008), "transcription activator-like effector nuclease" (TALEN) (Zu et al., 2013) and "targeting induced local lesions in genomes" (TILLING) (Moens et al., 2008). As these genetic tools may manipulate a wide range of zebrafish genes, the ability to apply informaticsdriven methods to systematically collect, store and analyze zebrafish pharmacogenetics data further empowers CNS drug discovery. For example, Figure 2E shows how increasing the "dimensionality" of traditional phenotypic screens by including an additional (genetic) dimension becomes a useful strategy of research in this field. Thus, systematic accumulation of pharmacogenetic evidence (with comparative analyses of drug response in wildtype vs. mutant fish) into large online data libraries becomes key for biomolecular data validation and generating novel mechanistic insights into drugs' action ( Figure 2E) as part of higher-throughput screening using zebrafish.

INCREASINGLY SOPHISTICATED BEHAVIORAL SCREENING TOOLS
The higher-throughput screening approach in today's drug discovery also becomes possible due to a combination of rapidly increasing computer processing power with sensitive videorecording tools that generate automated phenotypic data with high spatial and temporal resolution ( Figure 2E) (Cachat et al., 2011;Branson, 2014). In addition to testing individual fish with multiple individual endpoints to generate super-big data, simultaneous video-tracking of multiple fish swimming in groups (shoals) Branson, 2014;Kalueff et al., 2014b) is another strategy to achieve this goal. Moreover, recent advances in automated behavioral recognition (Glossary) further facilitate efficient in-vivo drug screens using zebrafish. For example, monitoring several zebrafish body points (e.g., nose, mid-body and tail) enables both automated quantification of fish locomotion and interpretation of complex zebrafish behaviors (e.g., chasing, biting, social approach or reduced sociability Kalueff et al., 2013) that parallel human phenotypes (see Stewart et al., 2014a for details).
Finally, as behavioral analyses become more efficient, stimuli that induce fish responses also become better standardized in zebrafish models. For example, currently available automated drug and/or food delivery tools improve zebrafish studies of drugs that affect reward mechanisms. Likewise, zebrafish operant behavior can be examined by using changes in zebrafish body position (e.g., swimming to a specific location) to deliver behavioral stimuli, such as punishment or reward. Exposing fish to predator or conspecific images on a computer screen (Luca and Gerlai, 2012), as well as using a computer-animated robotic "fish" (Butail et al., 2013;Cianca et al., 2013), represent other excellent examples of improved controllability of stimulus presentation in zebrafish models. Because stimulus delivery, behavioral quantification and phenotype recognition/interpretation are now increasingly computerized, zebrafish-based in-vivo screening in general is becoming more automated and higher-throughput.

CONCLUDING REMARKS
Fully automated robot-based screening platforms for larval and, eventually, adult zebrafish will soon become routine in zebrafish neurophenotyping studies. The HTS systems developed specifically for CNS drugs that affect complex behaviors will increase both the "width" and the "depth" of such screens (Figures 2D,E). Coupled with HTS, the ever increasing sophistication of genetic and behavior-recognition tools transform zebrafish models into higher-throughput in-vivo assays, allowing comprehensive coverage of the biological mechanisms of complex brain disorders, and leading to innovative CNS drug discovery. from zebrafish in-vivo screens. (D) Illustrated the extensive approach, testing a large number of drugs (D) in multiple animals (N) but recording few endpoints/phenotypes (P). This approach is markedly facilitated by using phenotypic barcoding approaches (Glossary). In contrast, the intensive approach screens few drugs, uses few animals but records many endpoints.

FIGURE 2 | Continued
The higher-throughput strategy, based on screening many compounds with multiple endpoints in a large number of animals, is empowered by locomotor pattern and behavioral recognition (Glossary) as well as automated slimuli delivery and experimental manipulations. (E) Shows the value of increased drug data "dimensionality" by including pharmacogenetic results (from wild type vs. mutant zebrafish) for providing important mechanistic insights into the drugs action. For example, a hypothetical antagonism of a drug A at a receptor R can be confirmed by screening the reference compound B (with known anti-R activity) and by mutating zebrafish gene R to abolish A/B-like activity in the mutants. Applying bioinformatics-based approaches and combining both lines of such evidence will facilitate the discovery of anti-R compounds (based on A-like pharmacology in zebrafish), followed by subsequent target validation in rodents and clinical studies.